Brind.
  1. Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.

Bristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.

3 reports, 2 independent Updated Nov 6
No new developments lately
Reports
3
Developments
2
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Bristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.

Who's involved

What this event is mainly about
Bristol-Myers SquibbNovartis

How it developed

Newest first. Tap a step to see who reported it.
  1. Both companies reported fatal events in autoimmune cell therapy trials.1 source
  2. BMY halts trials after Novartis experiences clinical setbacks.1 source

Keep exploring

Part of

Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story